Level of SARS-CoV-2 IgG Antibodies after Two Doses CoronaVac Vaccine: Primarily Report

Creative Commons License

Binay U. D., Karakeçili F., Barkay O., Gül Ö., Mertoğlu C.

Journal of Antivirals & Antiretrovirals, cilt.13, sa.S18, ss.1-4, 2021 (Hakemli Dergi)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: S18
  • Basım Tarihi: 2021
  • Dergi Adı: Journal of Antivirals & Antiretrovirals
  • Derginin Tarandığı İndeksler: Other Indexes
  • Sayfa Sayıları: ss.1-4
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic. CoronaVac vaccine is used in our country and we aimed to examine the level of antibody development after the second dose. Methods: This is a retrospective, cross-sectional research. The data of the people, who applied to a university hospital between January and March 2021, were analyzed. Those who had SARS-CoV-2 IgG and IgM measurement in the previous two weeks before the CoronoVac vaccine, and those who were both found negative and who had SARSCoV-2 IgG and IgM measurement after the second dose of CoronaVac vaccine were included in the research. of spike protein specific IgG/IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique. Results: 75 people were included in this research. It was found that the individuals had SARS-CoV-2 IgG and IgM measurements between 14 and 21 days after the first dose of CoronaVac vaccine. It was observed that 12% (n=9) of the cases had a history of COVID-19.The rate of positivity for SARS CoV-2 IgG level after vaccination was 100%. Conclusions: It can be said that two doses of CoronaVac vaccine create an effective humoral immunity. Keywords: COVID-19; CoronaVac vaccine; SARS-CoV-2 IgG